Effects of a Spine Navigation System on Op-time and Radiation Exposure

June 8, 2022 updated by: NYU Langone Health

Single Center, Prospective Study of the MvIGS Spine Navigation System in Posterior Fusion Utilizing Pedicle Screw Fixation

The goal of this study is to prospectively collect information about the operative time and intraoperative radiation experienced by patients undergoing posterior spinal fusion procedures guided by the MvIGS spine navigation system.

Study Overview

Detailed Description

This is a single-center, prospective case series to assess the use of the Machine-vision Image Guided Surgery (MvIGS) spine navigation system for treatment of spinal stenosis, scoliosis, and spondylolisthesis that requires fusion. This is a single-arm, open-label study. All participants will undergo their single and multi-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under MvIGS intraoperative navigation guidance.

Study Type

Interventional

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of spinal stenosis of the lumbar spine with degenerative spondylolisthesis, all grades, and planning to undergo surgical fusion;
  • Skeletally mature adults between the ages of 18-85 years at the time of surgery;
  • Has completed at least 6 months of conservative therapy for degenerative diagnosis, if appropriate; and,
  • Personally signed and dated an informed consent document prior to any study-related procedures, indicating that the patient has been informed of all pertinent aspects of the study.

Exclusion Criteria:

  • History of malignancy, craniocervical junction pathology, cervical and thoracic locations, and/or previous lumbar operation;
  • Significant peripheral neuropathy or acute denervation secondary to radiculopathy, caused by conditions other than spinal stenosis;
  • Significant peripheral vascular disease (defined as diminished dorsalis pedis or tibial pulses);
  • Morbid obesity, defined as BMI > 40 kg/m2;
  • Active systemic or local infection;
  • Active hepatitis (defined as receiving medical treatment within two years);
  • Immunocompromised, such as but not limited to being diagnosed with Acquired Immunodeficiency Syndrome (AIDS), HIV infection, Severe Combined Immunodeficiency Syndrome, or Thymic Hypoplasia;
  • Insulin-dependent diabetes mellitus or any other medical condition(s) that would represent a significant increase in surgical risk or interfere with normal healing;
  • Immunologically suppressed, or has received systemic steroids, excluding nasal steroids, at any dose daily for > 1 month within last 12 months;
  • History of Paget's disease, osteomalacia, or any other metabolic bone disease;
  • Involved in study of another investigational product that may affect outcome;
  • Women who are pregnant, lactating or anticipate becoming pregnant within 24 months post-surgery;
  • Non-English speaking;
  • Patients who are incarcerated;
  • Worker's compensation cases; or,
  • Patients involved in active litigation relating to his/her spinal condition.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: treatment group
Eligible participants will be identified by their treating physician and referred to the study research coordinator for enrollment. NYU standard practice in relation to pre-operative and intra-operative imaging studies will be explained. The role of the MvIGS system in this study will then also be explained. In each subject, they will perform posterior instrumentation utilizing the MvIGS spine navigation system for pedicle screw guidance and record data for intraoperative study endpoints

The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:

  • A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);
  • Proprietary imaging software (P/N 60-0007); and,
  • Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total length of operative time
Time Frame: Visit 1 Day 1
The aim is to reduce operative time. Operative time will be determined by the official recorded operative notes.
Visit 1 Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of time to register images
Time Frame: Visit 1 Day 1
Aim: To reduce time for registration of reference images Measured: Seconds
Visit 1 Day 1
Length of time to place all screws
Time Frame: Visit 1 Day 1
Aim: To reduce the time for screw placement Measured: Minutes
Visit 1 Day 1
Estimated blood loss (EBL)
Time Frame: Visit 1 Day 1
Aim: To reduce the EBL of each case Measured: Millilitres (mL)
Visit 1 Day 1
Dose of intraoperative ionizing radiation
Time Frame: Visit 1 Day 1
Aim: To reduce intraoperative ionizing radiation Measured: Total amount of the radiation dose in millisievert (mSv)
Visit 1 Day 1
Screw placement accuracy
Time Frame: Visit 1 Day 1
Aim: To improve screw placement accuracy Measured: Graded using radiographic classification and clinical revision rate
Visit 1 Day 1
incidence of intraoperative complications
Time Frame: Visit 1 Day 1
Aim: To decrease the incidence of intraoperative complications Measured: Number of reported complications
Visit 1 Day 1
Time to ambulation
Time Frame: Post operative hospital visit (Day 1-10)
Aim: To reduce time to ambulation Measured: Days
Post operative hospital visit (Day 1-10)
Time to hospital discharge after surgery
Time Frame: Post operative hospital visit (Day 1-10)
Aim: To reduce hospital length of stay Measured: Days
Post operative hospital visit (Day 1-10)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Jeffrey A Goldstein, MD, NYU Langone Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

July 1, 2022

Primary Completion (ANTICIPATED)

February 1, 2023

Study Completion (ANTICIPATED)

June 1, 2023

Study Registration Dates

First Submitted

June 30, 2020

First Submitted That Met QC Criteria

July 7, 2020

First Posted (ACTUAL)

July 8, 2020

Study Record Updates

Last Update Posted (ACTUAL)

June 13, 2022

Last Update Submitted That Met QC Criteria

June 8, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

IPD Sharing Time Frame

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

IPD Sharing Access Criteria

The investigator who proposed to use the data. Upon reasonable request. Requests should be directed to Jeffrey.goldstein@nyulangone.org . To gain access, data requestors will need to sign a data access agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Scoliosis

Clinical Trials on Machine-vision Image Guided Surgery (MvIGS) spine navigation system.

Subscribe